Akero Therapeutics, Inc.
AKRO
$54.20
-$0.70-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.54% | 22.06% | 26.89% | 10.61% | 6.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.12% | 65.11% | 97.39% | 86.02% | 73.15% |
| Operating Income | -50.12% | -65.11% | -97.39% | -86.02% | -73.15% |
| Income Before Tax | -50.30% | -66.09% | -98.29% | -76.75% | -60.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.30% | -66.09% | -98.29% | -76.75% | -60.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.30% | -66.09% | -98.29% | -76.75% | -60.30% |
| EBIT | -50.12% | -65.11% | -97.39% | -86.02% | -73.15% |
| EBITDA | -50.12% | -65.13% | -97.44% | -86.07% | -73.20% |
| EPS Basic | -17.04% | -31.36% | -59.03% | -33.20% | -16.99% |
| Normalized Basic EPS | -16.42% | -31.24% | -54.30% | -28.89% | -12.97% |
| EPS Diluted | -17.03% | -31.35% | -59.00% | -33.18% | -17.02% |
| Normalized Diluted EPS | -16.42% | -31.24% | -54.30% | -28.89% | -12.97% |
| Average Basic Shares Outstanding | 29.36% | 27.76% | 26.07% | 30.16% | 32.64% |
| Average Diluted Shares Outstanding | 29.36% | 27.76% | 26.07% | 30.16% | 32.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |